Balyasny Asset Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $35.6M | Sell |
566,312
-448,534
| -44% | -$31.2M | 0.05% | 472 |
|
|
2025
Q4 | $67.4M | Sell |
1,014,846
-616,536
| -38% | -$39.9M | 0.09% | 260 |
|
|
2025
Q3 | $110M | Buy |
1,631,382
+1,300,696
| +393% | +$103M | 0.14% | 153 |
|
|
2025
Q2 | $28.9M | Buy |
+330,686
| New | +$25.9M | 0.04% | 527 |
|
|
2025
Q1 | – | Sell |
-312,975
| Closed | -$25.5M | – | 2898 |
|
|
2024
Q4 | $24.3M | Sell |
312,975
-127,802
| -29% | -$9.46M | 0.04% | 574 |
|
|
2024
Q3 | $29.5M | Buy |
+440,777
| New | +$36.2M | 0.05% | 489 |
|
|
2024
Q2 | – | Sell |
-280,568
| Closed | -$38.9M | – | 2691 |
|
|
2024
Q1 | $38.9M | Buy |
280,568
+277,484
| +8,998% | +$34.9M | 0.07% | 392 |
|
|
2023
Q4 | $383K | Buy |
+3,084
| New | +$315K | ﹤0.01% | 2064 |
|
|
2023
Q2 | – | Sell |
-930,319
| Closed | -$108M | – | 2392 |
|
|
2023
Q1 | $108M | Sell |
930,319
-65,608
| -7% | -$7.34M | 0.27% | 76 |
|
|
2022
Q4 | $113M | Buy |
995,927
+391,766
| +65% | +$43M | 0.31% | 65 |
|
|
2022
Q3 | $48.7M | Sell |
604,161
-551,979
| -48% | -$46.8M | 0.15% | 159 |
|
|
2022
Q2 | $86.2M | Buy |
1,156,140
+630,248
| +120% | +$57.5M | 0.28% | 61 |
|
|
2022
Q1 | $67.3M | Buy |
525,892
+373,684
| +246% | +$40.9M | 0.21% | 83 |
|
|
2021
Q4 | $20.4M | Buy |
+152,208
| New | +$21.9M | 0.07% | 401 |
|
|
2020
Q2 | – | Sell |
-438,344
| Closed | -$29.5M | – | 1206 |
|
|
2020
Q1 | $29.5M | Sell |
438,344
-24,972
| -5% | -$1.55M | 0.35% | 63 |
|
|
2019
Q4 | $25.3M | Buy |
463,316
+157,916
| +52% | +$7.49M | 0.15% | 206 |
|
|
2019
Q3 | $11.4M | Sell |
305,400
-113,008
| -27% | -$4.39M | 0.08% | 362 |
|
|
2019
Q2 | $15.7M | Sell |
418,408
-545,892
| -57% | -$17.2M | 0.1% | 279 |
|
|
2019
Q1 | $28.7M | Buy |
964,300
+773,916
| +407% | +$27.2M | 0.19% | 155 |
|
|
2018
Q4 | $5.7M | Sell |
190,384
-993,428
| -84% | -$31.5M | 0.04% | 481 |
|
|
2018
Q3 | $42.3M | Buy |
1,183,812
+32,716
| +3% | +$1.01M | 0.19% | 139 |
|
|
2018
Q2 | $27.3M | Sell |
1,151,096
-336,444
| -23% | -$7.13M | 0.12% | 223 |
|
|
2018
Q1 | $27.6M | Buy |
1,487,540
+36,248
| +2% | +$536K | 0.12% | 245 |
|
|
2017
Q4 | $20.8M | Buy |
1,451,292
+355,620
| +32% | +$4.62M | 0.07% | 391 |
|
|
2017
Q3 | $13.4M | Buy |
1,095,672
+1,082,040
| +7,938% | +$19.1M | 0.05% | 415 |
|
|
2017
Q2 | $249K | Buy |
+13,632
| New | +$252K | ﹤0.01% | 1343 |
|
|
2016
Q4 | – | Sell |
-162,828
| Closed | -$3.57M | – | 1383 |
|
|
2016
Q3 | $3.57M | Sell |
162,828
-77,172
| -32% | -$1.72M | 0.02% | 553 |
|
|
2016
Q2 | $4.76M | Buy |
+240,000
| New | +$4.09M | 0.03% | 517 |
|
|
2015
Q4 | – | Sell |
-34,200
| Closed | -$734K | – | 1283 |
|
|
2015
Q3 | $734K | Buy |
+34,200
| New | +$763K | 0.01% | 769 |
|
Other funds holding DXCM
VCM
VPM
Balyasny Asset Management's DXCM Position: Q1 2026 in Review
Balyasny Asset Management reduced its DexCom (DXCM) stake by 44% in Q1 2026, selling an estimated $31.2M and leaving 566,312 shares worth $35.6M. The position accounts for 0.05% of the portfolio, ranked #472.
Balyasny Asset Management first reported a position in DXCM in Q3 2015 and has held it in 29 quarters since. The position peaked at $113M in Q4 2022. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Balyasny Asset Management held 566,312 shares of DexCom worth $35.6M as of Q1 2026.
- Balyasny Asset Management sold 448,534 DexCom shares in Q1 2026, an estimated $31.2M.
- DexCom made up 0.05% of Balyasny Asset Management's portfolio in Q1 2026, its #472 holding.
- Balyasny Asset Management first reported a position in DexCom in Q3 2015 and has held it in 29 quarters since.
- Balyasny Asset Management's DexCom position peaked at $113M in Q4 2022.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.